Kamada (KMDA) Tax Provisions (2012 - 2026)
Kamada's (KMDA) quarterly Tax Provisions came in at -$927000.0 in Q2 2026, down 157.12% on a YoY basis from $1.6 million in Q2 2025, and up 26.37% quarter-over-quarter from -$1.3 million in Q1 2026.
Analysis
Kamada (KMDA) Tax Provisions (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Tax Provisions for 13 consecutive years, with -$927000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Tax Provisions fell 157.12% year-over-year to -$927000.0; the trailing twelve-month figure through Jun 2026 stood at -$4.4 million (down 1953.14% YoY), and the FY2025 full-year result was -$3.3 million, down 389.8% from the prior year.
- Tax Provisions grew to -$927000.0 in Q2 2026 per KMDA's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Tax Provisions topped out at $1.6 million in Q2 2025 and bottomed at -$2.6 million in Q1 2025.
- Historically, Tax Provisions has averaged -$225111.1 across 5 years, with a median of $5500.0 in 2022.
- The sharpest annual moves came in 2024 and 2025: Tax Provisions surged 3867.65% in 2024, then sank 3479.73% in 2025.
- Over 5 years, Tax Provisions stood at $2000.0 in 2022, then soared by 1600.0% to $34000.0 in 2023, then soared by 3867.65% to $1.3 million in 2024, then sank by 186.88% to -$1.2 million in 2025, then advanced by 20.9% to -$927000.0 in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered -$927000.0, -$1.3 million, and -$1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | 393.00 Mn |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | 242.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | 292.00 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | 230.90 Mn |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | -59.00 Mn |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | 15.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | 34.90 Mn |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | -3.96 Mn |
| 10 | Kamada | 473.28 Mn | 403.14 Mn | 22.47 Mn | -927,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -927,000.00 |
| Mar 31, 2026 | -1.26 Mn |
| Dec 31, 2025 | -1.17 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | -2.65 Mn |
| Dec 31, 2024 | 1.35 Mn |
| Sep 30, 2024 | -84,000.00 |
| Jun 30, 2024 | -63,000.00 |
| Mar 31, 2024 | -74,000.00 |
| Dec 31, 2023 | 34,000.00 |
| Sep 30, 2023 | 73,000.00 |
| Jun 30, 2023 | 93,000.00 |
| Mar 31, 2023 | 13,000.00 |
| Dec 31, 2022 | 2,000.00 |
| Sep 30, 2022 | 10,000.00 |
| Jun 30, 2022 | 9,000.00 |
| Mar 31, 2022 | 41,000.00 |
| Dec 31, 2020 | 281,000.00 |
| Sep 30, 2020 | 348,000.00 |